alias:: HF, Congestive Heart Failure (CHF)  
ICD-11_Code:: BD10-BD1Z  
tags:: disease, cardiovascular

- ## Etiology  
  background-color:: blue
	- ### Causative Agents
		- N/A (Non-infectious)
	- ### Risk Factors
		- Coronary artery disease (CAD)
		- Hypertension
		- Diabetes mellitus
		- Obesity
		- Smoking
		- Valvular heart disease
		- Cardiomyopathies
		- Chronic kidney disease
- ## Epidemiology  
  background-color:: blue
	- ### Incidence
		- ~10 per 1,000 population (age >65)
	- ### Prevalence
		- ~64 million globally
		- ### Demographics
			- More common in elderly
			- Slightly higher in males
	- ### Geographic Distribution
		- Higher in high-income countries (due to aging populations)
- ## Pathophysiology  
  background-color:: blue
	- ### Mechanism of Disease
		- Impaired ventricular filling/ejection → Reduced cardiac output
		- Compensatory mechanisms (RAAS activation, sympathetic overdrive)
	- ### Affected Systems/Organs
		- Heart, lungs (pulmonary edema), kidneys (fluid retention), liver (congestion)
- ## Clinical Features  
  background-color:: blue
	- ### Clinical Presentation
		- #### Symptoms
			- Dyspnea (rest/exertion)
			- Fatigue
			- Peripheral edema
			- Orthopnea, PND
		- #### Signs
			- Elevated JVP
			- Crackles on auscultation
			- S3 gallop
	- ### Stages or Classification
		- ### Stages or Classification  
		  background-color:: #d4f1f9
			- #### NYHA Functional Classification (Symptom Severity)  
			  | **Class** | **Description** | **Key Features** |  
			  |---|---|---|  
			  | **I** | No limitations | Ordinary activity doesn’t cause symptoms |  
			  | **II** | Mild limitation | Comfortable at rest, but ordinary activity causes symptoms (e.g., dyspnea/fatigue) |  
			  | **III** | Marked limitation | Comfortable at rest, but < ordinary activity causes symptoms |  
			  | **IV** | Symptoms at rest | Unable to carry out any activity without discomfort |
			- #### ACC/AHA Stages (Disease Progression)  
			  | **Stage** | **Description** | **Clinical Action** |  
			  |---|---|---|  
			  | **A** | At risk (no structural disease) | Risk factor control (e.g., HTN, DM) |  
			  | **B** | Structural heart disease (no symptoms) | ACEi/ARB, beta-blockers if reduced EF |  
			  | **C** | Symptomatic HF | Guideline-directed medical therapy (GDMT) |  
			  | **D** | Refractory HF | Advanced therapies (LVAD/transplant) |
			- | **Type**               | **Key Features**                          | **Common Causes**                     | **Typical Presentation**               | **Diagnostic Clues**                     |  
			  |------------------------|------------------------------------------|---------------------------------------|----------------------------------------|------------------------------------------|  
			  | **Acute HF**           | Sudden onset, life-threatening          | MI, myocarditis, valve rupture       | Pulmonary edema, cyanosis, hypotension | BNP >500, CXR "bat-wing" pattern         |  
			  | **Chronic HF**         | Gradual progression, stable symptoms    | Hypertension, CAD, cardiomyopathy    | Fatigue, dyspnea on exertion, edema   | BNP 100-500, echocardiographic remodeling |  
			  | **Left-Sided HF**      | Pulmonary congestion (↑ LV pressure)    | HTN, aortic stenosis, LV infarction  | Orthopnea, crackles, S3 gallop         | Echo: LVEF <40%, E/e' >15 (diastolic)    |  
			  | **Right-Sided HF**     | Systemic congestion (↑ RV pressure)     | COPD, pulmonary HTN, RV infarction   | JVD, hepatomegaly, ascites             | Echo: RV dilation, TR velocity >2.8 m/s  |  
			  | **Congestive HF**      | Biventricular failure (global congestion) | Advanced cardiomyopathy, valvular disease | Anasarca, dyspnea at rest           | BNP >1000, bilateral pleural effusions   |
			- **Key Differences**:
				- NYHA: Tracks **symptom variability** (can fluctuate over time).
				- ACC/AHA: Reflects **irreversible progression** (cannot regress stages).
				- Example: A patient with LVEF 30% but asymptomatic = **ACC/AHA Stage B + NYHA Class I**.
				- Acute : Emergency(↑↑BNP, hypoxia).
				- Chronic = Stable but progressive (↑BNP, exercise intolerance).
				- Left = **Lung symptoms** (dyspnea, frothy sputum).
				- Right = **Body swelling** (leg edema, ascites).
				- Congestive : **Both ventricles fail** → "Wet and cold" profile (fluid overload + poor perfusion).
- ## Diagnosis  
  background-color:: blue
	- ### Diagnostic Criteria
		- Framingham / ESC criteria (Symptoms + Signs + Objective evidence)
	- ### Investigation
		- ### Establishing Diagnosis
			- BNP/NT-proBNP
			- Echocardiography (LVEF assessment)
			- CXR (cardiomegaly, pulmonary congestion)
		- ### Ruling Out Differential Diagnosis
			- | **Differential Diagnosis** | **Shared Features** | **Clinical Exclusion** | **Baseline Workup** (Perform even if no suspicion) | **Direct Testing** (Perform if suspicion) |
			  |---|---|---|---|---|
			  | COPD | Dyspnea | Absence of wheezing, smoking history | Spirometry | CT chest |
			  | Renal failure | Edema | No elevated JVP/hepatic congestion | Creatinine, eGFR | Renal ultrasound |
			  | Cirrhosis | Ascites | No cardiomegaly/BNP elevation | LFTs | Liver elastography |
		- ### General Assessment
			- ECG, electrolytes, renal function
- ## Management and Treatment  
  background-color:: blue
	- ### Medical Treatment
		- | **Therapy** | **Left-Sided HF** *(LV Failure)* | **Right-Sided HF** *(RV Failure)* | **Acute HF** *(Decompensated)* | **Congestive HF** *(Biventricular)* |
		  | ---- | ---- | ---- | ---- | ---- |
		  | **ACEi/ARB/ARNI** | ✅ **First-line** (reduces afterload) | ❌ Avoid if hypotensive | ❌ Delay until stable | ✅ Use cautiously (monitor BP/kidneys) |
		  | **Beta-blockers** | ✅ Start low (carvedilol/bisoprolol) | ❌ Avoid in severe RV failure | ❌ Hold during acute phase | ✅ Resume once euvolemic |
		  | **MRAs** | ✅ If LVEF ≤35% | ❌ Avoid with hepatic/renal dysfunction | ❌ High risk of renal injury | ✅ Low-dose + monitor K<sup>+</sup> |
		  | **SGLT2 inhibitors** | ✅ All LVEF ranges | ✅ Emerging evidence | ❌ Initiate post-stabilization | ✅ Reduces fluid overload |
		  | **Diuretics** | ✅ For pulmonary congestion | ✅ **Mainstay** (higher doses) | ✅ **IV loop diuretics** (e.g., furosemide bolus) | ✅ Aggressive fluid removal |
	- ### Surgical Options
		- **Left-Sided HF**:
			- **ICD/CRT** if LVEF ≤35% + symptoms.
			- **LVAD/Transplant** for end-stage.
		- **Right-Sided HF**:
			- Treat **underlying cause** (e.g., pulmonary HTN therapies).
			- **LVAD contraindicated** if isolated RV failure.
		- **Acute HF**:
			- Temporary **mechanical support** (e.g., IABP, ECMO).
		- **Congestive HF**:
			- **Ultrafiltration** if diuretic-resistant.
	- ### Lifestyle and Dietary Recommendations
		- #### **Lifestyle & Monitoring**
		  
		  | **Type** | **Dietary Focus** | **Activity** | **Monitoring** |
		  | ---- | ---- | ---- |
		  | **Left-Sided HF** | Sodium restriction (<2g/day) | Gradual cardiac rehab | BNP, echo (LVEF trends) |
		  | **Right-Sided HF** | **Fluid restriction** (<1.5L/day) | Leg elevation for edema | Daily weights, liver function |
		  | **Acute HF** | NPO initially | Bedrest | Hourly urine output, lactate |
		  | **Congestive HF** | **Strict fluid/sodium limits** | Limited mobility | CVP monitoring, renal function |
	- ### **Key Adjustments from General HF Management**
		- **Right-Sided HF**:
			- Prioritize **diuretics** over afterload reducers (ACEi/ARB may worsen hypotension).
			- Avoid **excessive diuresis** (can reduce RV preload → shock).
		- **Acute HF**:
			- **Immediate IV diuretics + vasodilators** (e.g., nitroglycerin).
			- **Inotropes** (e.g., dobutamine) if cardiogenic shock.
		- **Congestive HF**:
			- **Combination diuretics** (loop + thiazide) for refractory edema.
			- Early **palliative care** referral for Stage D.
		- **Left vs. Right**:
			- **ARNI** (sacubitril/valsartan) benefits **LV failure only**.
			- **Beta-blockers** may worsen RV failure if not titrated carefully.
	- ### **When to Escalate Therapy?**
		- **Left-Sided HF**: LVEF <20% → Consider transplant listing.
		- **Right-Sided HF**: Rising JVP + ascites → Ultrafiltration.
		- **Acute HF**: Lactate >2 → ICU transfer for vasoactive drugs.
	- ### Follow-up
		- Regular BNP, echocardiograms
- ## Prognosis  
  background-color:: blue
	- | **Type** | **1-Year Survival (With Treatment)** | **1-Year Survival (Without Treatment)** | **Key Complications (Untreated)** |
	  | ---- | ---- | ---- |
	  | **Left-Sided HF** | 80% (mild), 50% (severe) | <30% (severe) | Pulmonary edema, sudden cardiac death |
	  | **Right-Sided HF** | 60% (isolated), 40% (with PH) | 20-30% | Liver failure, renal collapse, cachexia |
	  | **Acute HF** | 70% (if stabilized) | <20% (if cardiogenic shock) | Multi-organ failure, arrhythmias |
	  | **Congestive HF** | 30-50% (Stage D) | <10% | Thromboembolism, anasarca, cardiac arrest |
	- ### Quality of Life Considerations
		- Frequent hospitalizations, activity limitations
- ## Prevention  
  background-color:: blue
	- ### Health Education
		- BP/Diabetes control
	- ### Community Approach
		- Smoking cessation programs
	- ### Screening Programs
		- Echocardiography for high-risk
	- ### Lifestyle Modifications
		- Exercise, Mediterranean diet
- ## Patient Education and Support  
  background-color:: blue
	- ### Educational Resources
		- AHA/ESC patient materials
	- ### Support Groups
		- Local HF associations
	- ### Counseling Options
		- Palliative care integration
- ## Recent Research and Developments  
  background-color:: blue
	- ### Ongoing Clinical Trials
		- Gene therapies
		- Novel MRA agents
	- ### Recent Advances
		- SGLT2 inhibitors (2020s paradigm shift)
- ## Key Literature  
  background-color:: blue
	- PARADIGM-HF, DAPA-HF trials
- ## Guidelines and Protocols  
  background-color:: blue
	- 2022 AHA/ACC/HFSA Guidelines
	- 2021 ESC Guidelines